Ryvu Therapeutics S.A.
RVU.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 77,968 | PLN 46,860 | PLN 38,804 | PLN 11,186 |
| % Growth | 66.4% | 20.8% | 246.9% | – |
| Cost of Goods Sold | PLN 19,580 | PLN 17,554 | PLN 17,406 | PLN 13,725 |
| Gross Profit | PLN 58,388 | PLN 29,306 | PLN 21,398 | -PLN 2,539 |
| % Margin | 74.9% | 62.5% | 55.1% | -22.7% |
| R&D Expenses | PLN 0 | PLN 0 | PLN 25,992 | PLN 15,018 |
| G&A Expenses | PLN 0 | PLN 0 | PLN 5,557 | PLN 4,330 |
| SG&A Expenses | PLN 4,495 | PLN 5,670 | PLN 5,557 | PLN 4,330 |
| Sales & Mktg Exp. | PLN 0 | PLN 0 | PLN 0 | PLN 0 |
| Other Operating Expenses | PLN 175,992 | PLN 124,584 | PLN 61,523 | PLN 56,630 |
| Operating Expenses | PLN 180,487 | PLN 130,254 | PLN 93,072 | PLN 75,978 |
| Operating Income | -PLN 122,099 | -PLN 100,948 | -PLN 78,422 | -PLN 103,783 |
| % Margin | -156.6% | -215.4% | -202.1% | -927.8% |
| Other Income/Exp. Net | PLN 10,961 | PLN 8,836 | -PLN 773 | -PLN 363 |
| Pre-Tax Income | -PLN 111,138 | -PLN 92,112 | -PLN 79,195 | -PLN 78,962 |
| Tax Expense | PLN 297 | PLN 0 | PLN 4,587 | PLN 116 |
| Net Income | -PLN 111,435 | -PLN 92,112 | -PLN 83,782 | -PLN 79,078 |
| % Margin | -142.9% | -196.6% | -215.9% | -706.9% |
| EPS | -4.82 | -4.02 | -4.57 | -4.31 |
| % Growth | -19.9% | 12% | -6% | – |
| EPS Diluted | -4.82 | -4.02 | -4.57 | -4.31 |
| Weighted Avg Shares Out | 23,120 | 22,898 | 18,335 | 18,355 |
| Weighted Avg Shares Out Dil | 23,120 | 22,898 | 18,335 | 18,355 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 9,128 | PLN 13,833 | PLN 1,145 | PLN 61 |
| Interest Expense | PLN 3,808 | PLN 97 | PLN 1,089 | PLN 442 |
| Depreciation & Amortization | PLN 10,496 | PLN 10,972 | PLN 12,900 | PLN 12,561 |
| EBITDA | -PLN 96,834 | -PLN 81,044 | -PLN 65,206 | -PLN 65,959 |
| % Margin | -124.2% | -172.9% | -168% | -589.6% |